Bio Impact Capital LLC Geron Corp Transaction History

Bio Impact Capital LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.75 - $3.44 $419,903 - $825,410	-239,945 Reduced 2.24%	10,475,675 $34.6 Million
Q4 2023 Feb 13, 2024	BUY	$1.74 - $2.31 $2.65 Million - $3.52 Million	1,524,330 Added 16.58%	10,715,620 $22.6 Million
Q2 2023 Aug 14, 2023	BUY	$1.97 - $3.69 $1.56 Million - $2.91 Million	789,725 Added 9.4%	9,191,290 $29.5 Million
Q1 2023 May 12, 2023	SELL	$2.14 - $3.4 $139,990 - $222,414	-65,416 Reduced 0.77%	8,401,565 $18.2 Million
Q4 2022 Feb 14, 2023	BUY	$2.03 - $2.42 $90,129 - $107,445	44,399 Added 0.53%	8,466,981 $20.5 Million
Q3 2022 Nov 14, 2022	SELL	$1.67 - $2.94 $20,723 - $36,482	-12,409 Reduced 0.15%	8,422,582 $19.7 Million
Q2 2022 Aug 11, 2022	BUY	$1.19 - $1.65 $2.72 Million - $3.77 Million	2,285,714 Added 37.17%	8,434,991 $13.1 Million
Q1 2022 May 13, 2022	BUY	$0.99 - $1.6 $520,134 - $840,620	525,388 Added 9.34%	6,149,277 $8.36 Million
Q4 2021 Feb 11, 2022	SELL	$1.22 - $1.72 $132,834 - $187,275	-108,881 Reduced 1.9%	5,623,889 $6.86 Million
Q3 2021 Nov 15, 2021	BUY	$1.2 - $1.5 $6.88 Million - $8.6 Million	5,732,770 New	5,732,770 $7.85 Million

276

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.08B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Bio Impact Capital LLC with notifications on news.